Clinical Trials Logo

Metastatic Cancer clinical trials

View clinical trials related to Metastatic Cancer.

Filter by:

NCT ID: NCT00886782 Terminated - Metastatic Cancer Clinical Trials

A Study of BMS-863233 in Patients With Advanced and/or Metastatic Solid Tumors

Start date: May 31, 2009
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine safety, tolerability and maximum tolerated dose of BMS-863233 in subjects advanced and/or Metastatic solid tumors.

NCT ID: NCT00875355 Recruiting - Breast Cancer Clinical Trials

Radiation Therapy With or Without Temozolomide in Treating Women With Brain Metastases and Breast Cancer

Start date: November 2007
Phase: Phase 2
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given alone or together with temozolomide in treating brain metastases secondary to breast cancer. PURPOSE: This randomized phase II trial is studying how well radiation therapy given together with temozolomide works compared with radiation therapy given alone in treating women with brain metastases and breast cancer.

NCT ID: NCT00874211 Completed - Breast Cancer Clinical Trials

S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases

Start date: December 2008
Phase:
Study type: Observational

RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care. PURPOSE: This clinical trial is studying osteonecrosis of the jaw in patients with cancer who are receiving zoledronic acid for bone metastases.

NCT ID: NCT00861107 Completed - Metastatic Cancer Clinical Trials

In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation

Start date: August 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase I/II study to investigate the feasibility of creating a personalized therapeutic cancer vaccine within the body. A vaccine contains a source of tumor antigen and an adjuvant. In this study, tumor antigen is generated by freezing a tumor by a minimally invasive percutaneous (through the skin) cryoablation procedure. The study drug, AlloStim, is injected into the ablated tumor to promote development of an anti-tumor immune response.

NCT ID: NCT00858429 Completed - Metastatic Cancer Clinical Trials

Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases

Start date: April 1, 2009
Phase: Phase 1
Study type: Interventional

RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy, such as yttrium Y 90 glass microspheres that deliver a high dose of radiation directly to the tumor, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Capecitabine may also make tumor cells more sensitive to radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of yttrium Y 90 glass microspheres when given together with capecitabine in treating patients with liver cholangiocarcinoma or liver metastases.

NCT ID: NCT00855803 Completed - Pain Clinical Trials

Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis

Start date: February 2009
Phase: Phase 2
Study type: Interventional

RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Vertebroplasty may help prevent fractures and spinal cord compression caused by spinal metastasis. Giving stereotactic body radiation therapy together with vertebroplasty may help lessen pain and improve quality of life of patients with spinal metastasis. PURPOSE: This phase II trial is studying how well giving stereotactic body radiation therapy together with vertebroplasty works in treating patients with localized spinal metastasis.

NCT ID: NCT00853528 Completed - Metastatic Cancer Clinical Trials

Stereotactic Radiosurgery in Treating Patients With Spinal Metastases

Start date: January 2009
Phase: Phase 1
Study type: Interventional

RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. It may also help patients with spinal metastases live more comfortably. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating patients with spinal metastases.

NCT ID: NCT00837928 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors

Start date: February 19, 2009
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Stereotactic radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of bendamustine when given together with radiation therapy in treating patients with brain metastases caused by solid tumors.

NCT ID: NCT00821860 Completed - Metastatic Cancer Clinical Trials

Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma

MesoVATS
Start date: September 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: Video-assisted surgery to remove part of the tissue layer covering the inside of the chest cavity may be effective in treating pleural effusion and cause less damage to normal tissue. Talc pleurodesis may keep fluid from building up in the chest cavity. It is not yet known which therapy is more effective in treating pleural effusion caused by malignant mesothelioma. PURPOSE: This randomized phase III trial is studying video-assisted surgery to see how well it works compared with talc pleurodesis in treating patients with malignant mesothelioma.

NCT ID: NCT00819169 Terminated - Colorectal Cancer Clinical Trials

QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors

Start date: January 2009
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multi-center, 2-part phase 1b/2 study of AMG 655 in combination with AMG 479 to be conducted in the United States and Spain. Part 1 is a dose escalation segment to identify a dose of AMG 655 in combination with AMG 479 that is safe and tolerable. Part 2 will evaluate the safety and estimate the efficacy of AMG 655 at the dose selected in Part 1 in combination with AMG 479 for the treatment of patients with advanced NSCLC (non-squamous histology; squamous histology), CRC, pancreatic cancer, ovarian cancer, and sarcoma.